Yes, BRCA1 is a tumor suppressor gene. Located on chromosome 17, it provides instructions for making a protein called breast cancer type 1 susceptibility protein, which helps prevent cells from growing and dividing uncontrollably. When both copies of BRCA1 are damaged or lost, cells lose a critical safeguard against cancer.
What BRCA1 Actually Does in Your Cells
Tumor suppressor genes work like brakes on cell growth. BRCA1 earns that classification because of two major jobs: repairing damaged DNA and controlling when cells are allowed to divide.
The most important role involves fixing a dangerous type of DNA damage called double-strand breaks, where both sides of the DNA ladder snap apart. Your cells face this kind of damage regularly from normal metabolism, radiation, and environmental exposures. BRCA1 pairs with a partner protein called BARD1 to coordinate a precise repair process. Together, they help enzymes chew back the broken ends of DNA in a controlled way, then guide other repair proteins to use an intact copy of the DNA as a template to rebuild the damaged section accurately. This process, called homologous recombination, is the most reliable method your cells have for fixing severe DNA damage without introducing errors.
BRCA1 also protects DNA during replication. When the machinery copying your DNA stalls (which happens more often than you might think), BRCA1 prevents the stalled site from being improperly chewed up. Research published in Nature showed that in the presence of certain protective proteins, the BRCA1-BARD1 pair actually switches roles and inhibits DNA degradation rather than promoting it. This dual ability, promoting controlled repair at breaks while blocking uncontrolled degradation at stalled replication sites, makes BRCA1 unusually versatile.
How BRCA1 Controls Cell Division
Beyond DNA repair, BRCA1 acts as a gatekeeper at multiple checkpoints in the cell division cycle. Before a cell commits to copying its DNA, BRCA1 helps activate p53, another well-known tumor suppressor, which can halt the process if damage is detected. This gives the cell time to make repairs before passing errors on to daughter cells.
BRCA1 participates in at least three distinct checkpoints. It helps stop cells from entering the DNA-copying phase when damage is present. It monitors for problems during DNA replication itself. And it helps prevent cells from physically dividing before damaged DNA has been addressed. At each of these stages, BRCA1 works with sensor proteins that detect damage and relay the “stop” signal through a chain of interactions. When BRCA1 is missing, cells barrel through these checkpoints with unrepaired DNA, accumulating mutations that can eventually drive cancer.
The Two-Hit Model of BRCA1 Loss
You inherit two copies of every gene, one from each parent. A principle first described by geneticist Alfred Knudson explains how tumor suppressor genes like BRCA1 are lost. One damaged copy alone isn’t enough to cause cancer because the remaining healthy copy can still produce functional protein. Cancer develops when the second copy is also knocked out through a later mutation, deletion, or silencing. This is known as the “two-hit” hypothesis.
People who inherit a harmful BRCA1 variant from a parent are born with the first hit already present in every cell. They need only one more event to lose BRCA1 function entirely in a given cell. People without an inherited variant need two separate, independent hits in the same cell, which is far less likely. This is why inherited BRCA1 mutations dramatically increase cancer risk compared to the general population, even though the biology of tumor suppression works the same way in both cases.
Cancer Risks Linked to BRCA1 Mutations
The cancers most strongly associated with BRCA1 mutations are breast and ovarian cancer. Women carrying a harmful BRCA1 variant have a lifetime breast cancer risk of approximately 60% by age 80, regardless of whether they have a family history of the disease. Lifetime ovarian cancer risk for BRCA1 carriers falls between 40% and 60% by the same age.
BRCA1 mutations also raise the risk of other cancers, though to a lesser degree. Men with BRCA1 mutations face an estimated 29% lifetime risk of prostate cancer by age 85. Pancreatic cancer risk reaches up to 5% for BRCA1 carriers. Male breast cancer, while rare overall, also occurs at higher rates in BRCA1 carriers than in the general population.
Why BRCA1 Loss Creates a Treatment Opportunity
The same DNA repair failure that makes BRCA1-deficient cells dangerous also makes them vulnerable. A class of drugs called PARP inhibitors exploits this weakness through a concept called synthetic lethality, where disabling two repair pathways simultaneously kills the cell, even though losing either one alone would be survivable.
Here’s how it works: your cells have backup repair systems for handling everyday DNA damage, including single-strand breaks (where only one side of the DNA ladder is nicked). A protein called PARP is central to one of these backup pathways. In normal cells, blocking PARP with a drug is no big deal because the cell can rely on BRCA1-dependent repair to handle any problems that escalate. But in cells that have already lost BRCA1, blocking PARP removes the last safety net. Single-strand breaks accumulate, convert into double-strand breaks during DNA replication, and the cell has no way to fix them. The damage becomes lethal. Importantly, PARP inhibitors also cause the PARP protein to become physically trapped on the DNA, creating roadblocks that stalled replication forks cannot resolve without functional BRCA1. This trapping effect is a major reason the drugs are so effective against BRCA1-deficient tumors while largely sparing normal cells, which still have working copies of BRCA1 to handle the damage.